Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

Corrie, P., Marshall, A., Dunn, J. et al. (17 more authors) (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, 15 (6). pp. 620-630. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Corrie, P.
  • Marshall, A.
  • Dunn, J.
  • Middleton, M.R.
  • Nathan, P.D.
  • Gore, M.E.
  • Davidson, D.
  • Nicholson, S.
  • Kelly, C.G.
  • Marples, M.
  • Danson, S.
  • Marshall, E.
  • Houston, S.
  • Board, R.E.
  • Waterston, A.M.
  • Nobes, J.P.
  • Harries, M.
  • Kumar, S.
  • Young, G.
  • Lorigan, P.
Copyright, Publisher and Additional Information: © Corrie et al. Open Access article distributed under the terms of CC BY
Dates:
  • Published: May 2014
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 22 Jun 2018 15:30
Last Modified: 22 Jun 2018 15:38
Published Version: https://doi.org/10.1016/S1470-2045(14)70110-X
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/S1470-2045(14)70110-X
Related URLs:

Download

Share / Export

Statistics